ReviewTranslational lung cancer research2014
Lung cancer screening guidelines: common ground and differences.
Review in Translational lung cancer research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Peutz-Jeghers Syndrome and lung cancer: does the risk meet the threshold for lung cancer screening?Familial cancer · 2026Review
- Evaluating lung cancer risk factors in adults with interstitial lung disease.Lung cancer (Amsterdam, Netherlands) · 2025Article
- Smoking cessation is a protective factor for lung cancer onset and mortality: a population-based prospective cohort study.BMC cancer · 2025Article
- Factors associated with adherence to provider referrals for lung cancer screening with low dose computed tomography before and during COVID-19 pandemic.BMC cancer · 2023Article
- Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges.Breathe (Sheffield, England) · 2022Review
- Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer.PloS one · 2020Article
- The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions.Population health metrics · 2018Article
- Trend analysis of major cancer statistics according to sex and severity levels in Korea.PloS one · 2018Article
- Risk assessment models for genetic risk predictors of lung cancer using two-stage replication for Asian and European populations.Oncotarget · 2017Article
- Urinary Metabolite Risk Biomarkers of Lung Cancer: A Prospective Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016Article
- Risk factors assessment and risk prediction models in lung cancer screening candidates.Annals of translational medicine · 2016Review
- Analysis of pulmonary function test results in a health check-up population.Journal of thoracic disease · 2015Article
- Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions.Translational lung cancer research · 2015Review
- EPHX1 rs2234922 polymorphism and lung cancer susceptibility in Asian populations: a meta-analysis.Journal of thoracic disease · 2015Article
- Geographic trends of tobacco-related cancers in Cyprus.Tobacco induced diseases · 2015Article
- Factors Associated With Obtaining Lung Cancer Screening Among Persons Who Smoke.MDM policy & practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer accounts for almost one-third of all cancer related deaths. Lung cancer risk persists even after smoking cessation and so many lung cancers now are diagnosed in former smokers. Five-year survival of lung cancer has marginally improved over decades and significantly lags behind that of colon, breast and prostate cancer. Over the past one decade, lung cancer screening trials have shown promising results. Results from National Lung Cancer Screening Trial (NLST), have shown a significant 20% reduction in mortality with annual low dose computed tomography (LDCT) screening. Based on these results, annual LDCT testing has been recommended for lung cancer screening in high risk population. However, development and acceptance of lung cancer screening as a public health policy is still in the nascent stages. Major concerns relate to risk of radiation, overdiagnosis bias, proportion of false positives and cost benefit analysis. This article reviews the literature pertaining to lung cancer screening guidelines and above mentioned concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.